Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02602795 · ClinicalTrials.gov registry record · NA

Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence

A NA study of HIV and Sexually Transmitted Diseases, sponsored by Rhode Island Hospital.

Completed
Registry status
NA
Development phase
14
Enrollment target
1
Study location

NCT02602795 is a NA study of HIV and Sexually Transmitted Diseases that has completed, run by Rhode Island Hospital. The registered enrollment target is 14 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02602795, a NA study of HIV and Sexually Transmitted Diseases, has completed, sponsored by Rhode Island Hospital.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

Before starting treatment with XR-NTX, a medication that blocks the positive effects of opioids and helps people stay off opioids, individuals who are dependent on opioids first have to endure a difficult withdrawal process. This study aims to develop and test an intervention to help people who are opioid dependent successfully complete that transition; the investigators will also develop and test a comparison condition aimed at reducing HIV risk behavior.

Interventions

  • BEHAVIORAL Acceptance and Commitment Therapy
  • BEHAVIORAL Information Motivation Behavioral Model

Study Locations (1)

Rhode Island

  • Rhode Island Hospital - Providence

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2015-12
Est. Completion 2018-06
Phase NA

Sponsor

Rhode Island Hospital

130 total trials

What the Registry Record Tells You About NCT02602795

The ClinicalTrials.gov registry entry for NCT02602795 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Acceptance and Commitment Therapy is the first listed.

NCT02602795 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT02602795 about?

NCT02602795 is a clinical study titled "Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence". Before starting treatment with XR-NTX, a medication that blocks the positive effects of opioids and helps people stay off opioids, individuals who are dependent on opioids first have to endure a difficult withdrawal process. This study aims to develop and test an intervention to help people who are ...

What is the current status of trial NCT02602795?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2015-12. Estimated completion is 2018-06.

What conditions does trial NCT02602795 study?

This clinical trial studies the following conditions: HIV, Sexually Transmitted Diseases, Opiate Dependence.

What interventions are being tested in trial NCT02602795?

The interventions under investigation include: Acceptance and Commitment Therapy (BEHAVIORAL), Information Motivation Behavioral Model (BEHAVIORAL).

Who is sponsoring clinical trial NCT02602795?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02602795 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.